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background:  MicroRNAs (miRs) regulate gene expression and may participate in coronary artery plaque rupture. This study compared patients 
with coronary artery disease (CAD) and subsequent myocardial infarction (preMI) and those with stable CAD (sCAD) for expression of 13 circulating 
miRs associated with cardiovascular pathologies.
methods: Plasma samples were obtained from consenting patients (pts) at angiography. PreMI samples (n=30) were collected 4-44 days 
before MI and compared with matched (age, gender, race, hyperlipidemia, hypertension, diabetes, disease burden) sCAD pts (n=30) without 
prior or subsequent (5 year) MI, excluding MiR-associated comorbidities. Mature plasma miRs-1,-9,-21,-122,-126,-134,-145,-197,-208,-133a,-
133b,-223,-375 were quantitated with TaqMan miRNA assays using miR-16 as endogenous control for normalization and are reported as normalized 
Ct (∆Ct). Fold differences were calculated with ∆∆Ct method. Mann-Whitney tests were performed at the 10% significance level with a continuity 
correction and adjustment for false-discovery rate (FDR) with adjusted significance set at q=0.1. Analyses compared sCAD with preMI for the whole 
sample set (primary analysis) and a subset of preMI (n=11) obtained 4-14 days prior to MI (preMI4-14).
results: In primary analysis, miR-122 was down-regulated (increased∆Ct) in preMI pts: 10.55 vs 8.34, p=0.009, q= 0.10, representing 4.6 fold 
reduction. In subset analysis, preMI4-14 samples had reduced miR-122 (10.98 vs 8.06 for sCAD, 7.6 fold difference, p=0.013, q= 0.09), miR-
126 (6.16 vs 4.04 for sCAD, 4.3 fold difference p=0.015, q=0.09) and miR-375 (12.78 vs 11.07 for sCAD, 3.2 fold difference, p=0.032, q= 0.12). 
MiR-122 and miR-126 remained significant following FDR correction, however it’s expected that one of these findings is a false positive. No miR 
differences were noted in preMI samples obtained 14-44 days prior to MI.
Conclusions: Plasma miR -122 or -126 is associated with subsequent MI, but only in the period 4-14 days prior to the event. These miRs may 
participate in or signal plaque destabilization. If replicated, these biomarkers might be useful in identifying patients at increased risk for impending 
MI. 
